Clinical TrialsSearch results
Number of results: 2562
Recruiting
- A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma
- Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
- Ueda Eiji
- 2021-02-12
Recruiting
- A phase 2 study of S-005151 in patients with dystrophic epidermolysis bullosa to evaluate the efficacy for intractable ulcers
- dystrophic epidermolysis bullosa
- Juan Carlos Gomez
- 2022-10-14
Recruiting
- A phase 2a study assessing the efficacy and safety of STN1010905 ophthalmic suspension in subjects with MGD
- MGD (Meibomian Gland Dysfunction)
- Migita Yukie
- 2024-06-18
Recruiting
- A phase 2a study of TAS5315 in patients with chronic spontaneous urticaria
- chronic spontaneous urticaria
- Ali Nasermoaddeli
- 2022-04-15
Recruiting
- A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke
- Patient with acute ischemic stroke
- Gomez Juan Carlos
- 2023-05-20
Recruiting
- A Phase 3 Study of Ravulizumab to Protect Patients with CKD from CSA-AKI and MAKE
- Chronic Kidney Disease CKD Cardiac Disease Cardiopulmonary Bypass
- Yokosawa Jun
- 2023-04-16
Recruiting
- A Phase 3 study of S-217622 in pediatric participants
- SARS-CoV-2 infection
- Gomez Juan Carlos
- 2023-06-16
Recruiting
- A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopenia (ITP) patients who failed steroids
- primary immune thrombocytopenia
- Yamauchi Kyosuke
- 2023-02-09
Recruiting
- A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept(ACE-536) clinical trials
- Anemia associated with myelodysplastic syndrom or myelofibrosis
- Hayakawa Jin
- 2022-10-28
Recruiting
- A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)
- congenital thrombotic thrombocytopenic purpura
- Iwasaki Tsubasa
- 2022-09-27